Xenetic Biosciences, Inc.
XBIOAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Neutral | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 20, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 5, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 16, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 2, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jan 11, 2021 |
| Ladenburg Thalmann | maintain | Buy | Nov 25, 2020 |
| Ladenburg Thalmann | maintain | Buy | Dec 20, 2016 |
Earnings History
Next report: Mar 25, 2027| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.41 | — | $660.6K | — |
| May 12, 2026 | $-0.20 | — | $806.9K | — |
| Mar 12, 2026 | $-0.22 | $-0.52 | $766.3K | $690.0K |
| Nov 12, 2025 | $-0.33 | $-0.49 | $1.0M | $630.0K |
| Aug 12, 2025 | $-0.45 | $-0.64 | $589.9K | $479.0K |
| May 12, 2025 | $-0.59 | $-0.72 | $590.0K | $670.0K |
| Mar 18, 2025 | $-0.68 | $-0.68 | $650.0K | $650.0K |
| Nov 12, 2024 | $-0.28 | $-0.14 | $614.2K | $750.0K |
News
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Institutional and Insider Ownership 15.1% of Xenetic Biosciences
First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expected in Q2 2027 FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announc…
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of
Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform.
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue Joint pipeline includes four first-in-class progr…